Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, a ... earned three Gold, three Silver, and three Bronze Stevie® ... held in Chicago this month.The ... premier business awards program in the U.S. ... company,s strength in developing leaders, cultivating talent, creating a ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... Ltd, enters strategic European alliances and gears up for business at ... ... Belfast (Vocus) May 11, 2009 -- The Northern Ireland ... Sepha Ltd is boosting its European distribution network ahead ...
... BioTrends Research Group released highlights from its baseline wave of ... research study that will track uptake of the drug from ... is based on results of a survey of 77 Rheumatologists ... of the Rheumatologists surveyed were aware of SIMPONI and about ...
... SAN DIEGO, May 8 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ... that the Company will be speaking at the following investor conferences: Bank ... Conference , Date: Tuesday, May 12, ... Location: The New York Palace Hotel, New York, ...
Cached Biology Technology:Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 2Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 3Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R) 2
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... SARS. Ebola. Bird Flu. Swine Flu. Rabies. These are ... one animal species into another and now infect humans. ... and scientists are working to determine what drives it. ... Tennessee, Knoxville, and department head in Ecology and Evolutionary ...
... (August 5, 2010) With global warming and climate ... reassuring to know that some creatures might cope by ... become less hospitable. Nevertheless, natural relocation of species is ... to Jessica Hellmann, Associate Professor at the University of ...
... , RIVERSIDE, Calif. Tobacco-related disease kills more people ... this problem, the University of California, Riverside has received ... Research Program ( TRDRP ), the most TRDRP grants ... more than $850,000, the grants will fund research on ...
Cached Biology News:UT professor uncovers clues into how viruses jump from hosts 2Butterflies shed light on how some species respond to global warming 2Butterflies shed light on how some species respond to global warming 3UC Riverside receives 6 grants for tobacco-related research 2UC Riverside receives 6 grants for tobacco-related research 3
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Biology Products: